Testoviron Depot

Testoviron Depot





Four Star
Concise Prescribing Info
Testosterone enantate
Dosage/Direction for Use
Stimulate development of underdeveloped androgen-dependent organs & for initial treatment of deficiency symptoms 250 mg as slow IM inj every 2-3 wk. Maintenance treatment 250 mg as slow IM inj every 3-6 wk, according to individual requirement.
Hypersensitivity. Androgen-dependent carcinoma of the prostate or of the male mammary gland; hypercalcaemia in cases of malignant tumours; past or present liver tumours. Women; small childn; newborn infants.
Special Precautions
Increased risk for the development of prostatic hyperplasia in older patients. Exclude prostatic cancer or risk of pre-existing prostatic cancer before starting therapy. May accelerate development of sub-clinical prostatic cancer & benign prostatic hyperplasia. Perform regular check-ups of the prostate gland & breast. Monitor testosterone level at baseline & at regular intervals during treatment. Regularly monitor Hb, haematocrit, liver function & blood lipid profile. Patients at risk of hypercalcemia (& associated hypercalciuria) eg, due to bone metastasis; patients w/ acquired or inherited bleeding disorders; thrombophilia; severe cardiac, hepatic, or renal insufficiency or ischaemic heart disease; pre-existing HTN; impaired renal or hepatic function; epilepsy or migraine; patients pre-disposed to oedema; diabetic patients. Reports of venous thromboembolic events, including DVT & pulmonary embolism; benign & malignant liver tumors. Permanently discontinue if symptoms of excessive androgen exposure persist or recur during therapy on the recommended dosing schedule. May accelerate bone maturation in childn. Not suitable for treatment of male sterility. Pre-existing sleep apnea may be potentiated. Positive results in doping tests. Not for enhancing muscular development or increasing physical ability. Concomitant use w/ coumarin-derived anticoagulants. May reversibly reduce spermatogenesis. Elderly >65 yr.
Adverse Reactions
Inj site pain, redness, cough &/or dyspnea during or immediately after inj. Haematocrit increased, RBC count increased, Hb increased.
Drug Interactions
Increased clearance of testosterone w/ barbiturates & other enzyme inducers. Increased serum levels of oxyphenbutazone. Increased effects of coumarin-derived oral anticoagulants. Possible oedema formation w/ ACTH or corticosteroids. Increased insulin sensitivity; adjust dose of insulin or other antidiabetics.
MIMS Class
Androgens & Related Synthetic Drugs
ATC Classification
G03BA03 - testosterone ; Belongs to the class of 3-oxoandrosten (4) derivative androgens used in androgenic hormone preparations.
Testoviron Depot depot inj 250 mg/mL
3 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in